[
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds",
    "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in […]",
    "url": "https://finnhub.io/api/news?id=69a67d28f25787a36e848fa3c19962a31e24e6f183b1db9fd845cb5dc5a43eca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741804014,
      "headline": "Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds",
      "id": 133184439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in […]",
      "url": "https://finnhub.io/api/news?id=69a67d28f25787a36e848fa3c19962a31e24e6f183b1db9fd845cb5dc5a43eca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)",
    "summary": "2025 Proxy Statement and Additional Definitive Proxy Solicitation Materials Definitive Proxy Statement, filed March 12, 2025 ...",
    "url": "https://finnhub.io/api/news?id=b1959e33189e69f08c2ecb71e923f3d09fd8dd831197c0e8c5302001cc3bca42",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741788012,
      "headline": "Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)",
      "id": 133156707,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "2025 Proxy Statement and Additional Definitive Proxy Solicitation Materials Definitive Proxy Statement, filed March 12, 2025 ...",
      "url": "https://finnhub.io/api/news?id=b1959e33189e69f08c2ecb71e923f3d09fd8dd831197c0e8c5302001cc3bca42"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : Meeting agenda (2025 Meeting agenda)",
    "summary": "Annual Shareholders Meeting April 24, 2025 Agenda Welcome 2024 Business Review ...",
    "url": "https://finnhub.io/api/news?id=7e62b462630aa1c7e37760ac208fd4a2100fabc8d461f8470a5614e1ff81d3ee",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741788011,
      "headline": "Johnson & Johnson : Meeting agenda (2025 Meeting agenda)",
      "id": 133156708,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Annual Shareholders Meeting April 24, 2025 Agenda Welcome 2024 Business Review ...",
      "url": "https://finnhub.io/api/news?id=7e62b462630aa1c7e37760ac208fd4a2100fabc8d461f8470a5614e1ff81d3ee"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy",
    "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the […]",
    "url": "https://finnhub.io/api/news?id=dd0b2104f844a45c1915f426e37c498508e1fce5856489d211fe78ede56c872f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741787233,
      "headline": "Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy",
      "id": 133184440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the […]",
      "url": "https://finnhub.io/api/news?id=dd0b2104f844a45c1915f426e37c498508e1fce5856489d211fe78ede56c872f"
    }
  },
  {
    "ts": null,
    "headline": "Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others",
    "summary": "Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.",
    "url": "https://finnhub.io/api/news?id=9cf9ca56103d930886a81f4fb47de06448e6f9ac30502d33ccf692493d220c13",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741786147,
      "headline": "Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others",
      "id": 133156626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2033001899/image_2033001899.jpg?io=getty-c-w750",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.",
      "url": "https://finnhub.io/api/news?id=9cf9ca56103d930886a81f4fb47de06448e6f9ac30502d33ccf692493d220c13"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=956ea71dbec957eb13e56f226baee7824bb92f9afee188ecc075d2e5a52dd366",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741784411,
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "id": 133184441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=956ea71dbec957eb13e56f226baee7824bb92f9afee188ecc075d2e5a52dd366"
    }
  },
  {
    "ts": null,
    "headline": "J&J Medtech gets regulatory clearance for its latest robotic-assisted bronchoscopy technology",
    "summary": "Johnson & Johnson: * JOHNSON & JOHNSON MEDTECH ANNOUNCES CLEARANCE OF MONARCHTMQUESTFOR ENHANCED ROBOTIC-ASSISTED BRONCHOSCOPYSource text: https://shorturl.at/Z2FcFFurther company...",
    "url": "https://finnhub.io/api/news?id=184f75287e3f9af0f06524355bc8c515925c7c2d8996dbde757921034a9e5912",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741774195,
      "headline": "J&J Medtech gets regulatory clearance for its latest robotic-assisted bronchoscopy technology",
      "id": 133149089,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * JOHNSON & JOHNSON MEDTECH ANNOUNCES CLEARANCE OF MONARCHTMQUESTFOR ENHANCED ROBOTIC-ASSISTED BRONCHOSCOPYSource text: https://shorturl.at/Z2FcFFurther company...",
      "url": "https://finnhub.io/api/news?id=184f75287e3f9af0f06524355bc8c515925c7c2d8996dbde757921034a9e5912"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
    "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
    "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741773660,
      "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
      "id": 133149109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
      "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae"
    }
  },
  {
    "ts": null,
    "headline": "J&J Says CEO Joaquin Duato's 2024 Total Compensation Was $24.3 Million Versus $28.4 Million In 2023 - SEC Filing",
    "summary": "Johnson & Johnson: * J&J SAYS CEO JOAQUIN DUATO'S 2024 TOTAL COMPENSATION WAS$24.3MILLION VERSUS $28.4 MILLION IN 2023 – SEC FILINGSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=6a7d3239f646b8bec364c7da424f13aab4a3bcc5e45235e5989e8c10ea726061",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741762039,
      "headline": "J&J Says CEO Joaquin Duato's 2024 Total Compensation Was $24.3 Million Versus $28.4 Million In 2023 - SEC Filing",
      "id": 133147840,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * J&J SAYS CEO JOAQUIN DUATO'S 2024 TOTAL COMPENSATION WAS$24.3MILLION VERSUS $28.4 MILLION IN 2023 – SEC FILINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=6a7d3239f646b8bec364c7da424f13aab4a3bcc5e45235e5989e8c10ea726061"
    }
  }
]